NEW YORK (GenomeWeb) – GenMark Diagnostics said Thursday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture ID – Gram Positive (BCID-GP) panel.
It is the first of three blood culture panels being developed on the ePlex molecular sample-to-answer system for the diagnosis and management of bloodstream infections that can lead to sepsis, the firm said.